Innocrin Pharmaceuticals, Inc. (Innocrin)

Oncology Corporate Profile

HQ Location

4505 Emperor Boulevard, Suite 300
Durham, NC 27703

Company Description

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
VT-464CYP17 lyase inhibitorProstate cancerII

View additional information on product candidates here »


Recent News Headlines

There are no news items to display